Cantor Fitzgerald set a $62.00 price target on Emergent Biosolutions (NYSE:EBS) in a report published on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

EBS has been the subject of a number of other research reports. Argus assumed coverage on Emergent Biosolutions in a research note on Wednesday, June 13th. They issued a buy rating and a $62.00 price target for the company. Wells Fargo & Co lowered Emergent Biosolutions from an outperform rating to a market perform rating and set a $56.00 price target for the company. in a research note on Tuesday, April 24th. Zacks Investment Research raised Emergent Biosolutions from a hold rating to a buy rating and set a $59.00 price target for the company in a research note on Monday, April 30th. Finally, Chardan Capital raised their price target on Emergent Biosolutions from $53.00 to $57.00 and gave the stock a buy rating in a research note on Friday, August 3rd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Emergent Biosolutions has an average rating of Buy and an average target price of $59.57.

Shares of EBS stock opened at $55.03 on Thursday. Emergent Biosolutions has a 52 week low of $32.48 and a 52 week high of $60.00. The firm has a market capitalization of $2.75 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 1.18 and a beta of 1.20. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. During the same quarter last year, the firm posted $0.13 earnings per share. The firm’s revenue was up 118.5% on a year-over-year basis. sell-side analysts anticipate that Emergent Biosolutions will post 2.33 EPS for the current fiscal year.

In other news, Director Kathryn C. Zoon sold 1,377 shares of the firm’s stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $51.15, for a total transaction of $70,433.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 15,785 shares of the firm’s stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total value of $822,556.35. Following the transaction, the chief executive officer now owns 197,343 shares of the company’s stock, valued at $10,283,543.73. The disclosure for this sale can be found here. Insiders have sold 52,538 shares of company stock valued at $2,798,946 in the last three months. Insiders own 13.40% of the company’s stock.

Several large investors have recently modified their holdings of EBS. Stratos Wealth Partners LTD. bought a new position in shares of Emergent Biosolutions during the first quarter valued at $134,000. PNC Financial Services Group Inc. increased its holdings in shares of Emergent Biosolutions by 108.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,482 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Emergent Biosolutions during the first quarter valued at $171,000. Financial Gravity Wealth Inc. bought a new position in shares of Emergent Biosolutions during the first quarter valued at $190,000. Finally, Sei Investments Co. increased its holdings in shares of Emergent Biosolutions by 5,992.1% during the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 3,775 shares in the last quarter. Hedge funds and other institutional investors own 82.72% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Book Value Per Share in Stock Trading

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.